Tech Company Financing Transactions

Tunitas Therapeutics Funding Round

Ally Bridge Group and WuXi PharmaTech joined a $10 million Series A funding round for Tunitas Therapeutics. The funding round was announced on 10/1/2015.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

409 Illinois St.
San Francisco, CA 94158
USA

Phone

(650) 887-4747

Website

www.tunitastherapeutics.com

Email Address

Not Recorded

Overview

Tunitas Therapeutics is a biopharmaceutical company that is developing novel and precisely targeted protein therapeutics with the potential to dramatically change the lives of allergy sufferers.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Nolan Sigal

        

Chief Financial Officer

Linda Rubinstein

        

Chief Scientific Officer

Andrew Saxon

        

VP - R & D

David King

        

Browse more venture capital transactions:

Prev: 10/1/2015: Slash venture capital transaction
Next: 10/1/2015: Neuromod Devices venture capital transaction

Share this article

About Our VC Transactions Data

We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary